Zobrazeno 1 - 10
of 19
pro vyhledávání: '"N. Ryabin"'
Autor:
Shannon Puhalla, Kimberly L. Blackwell, Eric P. Winer, Alarice C. Lowe, Roisin M. Connolly, Kenneth R. Hess, N. Ryabin, Nathalie Y. R. Agar, Jeffrey S. Wefel, Christina I. Herold, Nan Lin, Sarah Farooq, Polly A. Niravath, Mothaffar F. Rimawi, Elizabeth V. Lawler, Ian E. Krop, Nuhad K. Ibrahim, Rachel A. Freedman, Catherine Van Poznak, Minetta C. Liu, Beverly Moy, Michelle E. Melisko, Antonio C. Wolff, Rebecca Gelman
Publikováno v:
Journal of Clinical Oncology. 34:945-952
Purpose Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity in HER2-posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62f904cf47a641d600d4b1e85046451
https://doi.org/10.1200/jco.2015.63.0343
https://doi.org/10.1200/jco.2015.63.0343
Autor:
Tari A. King, Kandice K. Ludwig, Elizabeth V. Lawler, Shawna C. Willey, Clifford A. Hudis, Rebecca Gelman, Faina Nakhlis, J. Dirk Iglehart, E. Shelley Hwang, Lauren Gilmore, Stuart J. Schnitt, N. Ryabin, Isabelle Bedrosian, Mehra Golshan
Publikováno v:
Annals of Surgical Oncology. 23:722-728
Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e96d42582ddc905c314a744e66fc82
https://doi.org/10.1245/s10434-015-4922-4
https://doi.org/10.1245/s10434-015-4922-4
Autor:
S Shak, Erica L. Mayer, Kathy D. Miller, C Yoshizawa, Lisa A. Carey, HS Rugo, N. Ryabin, C Pomeroy, HJ Burstein, EP Winer
Publikováno v:
Cancer Research. 70:P3-10
Background Oncotype DX® Recurrence Score® (RS) provides both predictive and prognostic information for estrogen receptor positive (ER+) breast cancer. Whether RS evolves after exposure to chemotherapy (C), or if RS post-neoadjuvant C has prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::800e7d418cf198019f7c0d21e9af71d6
https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13
https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13
Autor:
Eric P. Winer, Ingrid A. Mayer, Julie Najita, Jeffrey T. Yap, Annick D. Van den Abbeele, Nan Lin, Mothaffar F. Rimawi, Ian E. Krop, Carla I. Falkson, E. Claire Dees, Carlos L. Arteaga, N. Ryabin, William T. Barry, Hao Guo, Antonio C. Wolff, Timothy J. Hobday, Rita Nanda, Andrea L. Richardson
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(24)
Purpose Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2–positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and expl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f227677f17f28d26ed746d7f621d84e
https://pubmed.ncbi.nlm.nih.gov/26195716
https://pubmed.ncbi.nlm.nih.gov/26195716
Publikováno v:
Immunopathology, Allergology, Infectology. :28-30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f4dee1b38b8cfcfef52e5c7b2f7f072
https://doi.org/10.14427/jipai.2013.4.28
https://doi.org/10.14427/jipai.2013.4.28
Autor:
Harold J. Burstein, N. Ryabin, Eric P. Winer, Margaret Haldoupis, Lawrence N. Shulman, Nan Lin, Rebecca Gelman, Steven E. Come, Leroy M. Parker
Publikováno v:
Investigational new drugs. 25(4)
This study evaluated the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-l-glutamate, in patients with HER2-negative, metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. Although CT-2103 had activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9607ec80138028318dca5380ba805e2e
https://pubmed.ncbi.nlm.nih.gov/17345004
https://pubmed.ncbi.nlm.nih.gov/17345004
Autor:
Minetta C. Liu, Jeffrey S. Wefel, Roisin M. Connolly, Elizabeth S Lawler, Nuhad K. Ibrahim, Michelle E. Melisko, Alarice C. Lowe, N. Ryabin, Antonio C. Wolff, Eric P. Winer, Polly A. Niravath, Catherine Van Poznak, Rebecca Gelman, Ian E. Krop, Nathalie Y. R. Agar, Shannon Puhalla, Nan Lin, Kimberly L. Blackwell, Rachel A. Freedman
Publikováno v:
Journal of Clinical Oncology. 32:528-528
528 Background: Evidence-based treatments for metastatic, HER2+ breast cancer to the central nervous system (CNS) are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4 with ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eec08f7ab3a999381bdeeefe1cb8179
https://doi.org/10.1200/jco.2014.32.15_suppl.528
https://doi.org/10.1200/jco.2014.32.15_suppl.528
Autor:
JN Ingle, Nu Lin, Jeffrey S. Wefel, Shannon Puhalla, Ian E. Krop, Rachel A. Freedman, Nyr Agar, K. L. Blackwell, C. Van Poznak, A Ly, Lisle Nabell, N. Ryabin, Antonio C. Wolff, EP Winer, Rebecca Gelman, Roisin M. Connolly, Polly A. Niravath, M. Melisko
Publikováno v:
Cancer Research. 72:OT1-1
Background: 1/3 of women with metastatic HER2+ breast cancer will develop central nervous system (CNS) metastases yet evidence-based treatments for women with progressive CNS disease are limited. Neratinib is an irreversible inhibitor of erbB1, HER2,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3820878c0d6cd28482e7869fc11ee903
https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-11
https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-11
Autor:
Kathy D. Miller, EP Winer, Jennifer A. Ligibel, Jeffrey Peppercorn, Andres Forero, Rebecca Gelman, IA Mayer, Antonio C. Wolff, PJ Pletcher, J Eng-Wong, N. Ryabin, Erica L. Mayer, HJ Burstein, Maura N. Dickler, Lisa A. Carey
Publikováno v:
Cancer Research. 71:OT3-02
Background Patients (pts) with residual breast cancer after neoadjuvant chemotherapy are at increased risk of recurrence; no proven risk-reduction strategies exist, supporting exploration of novel therapies in the post-preoperative setting. Bevacizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bd9a0dd5e7fea7f45a43d27afd8a3a0
https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04
https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04
Autor:
Antonio C. Wolff, N. Ryabin, Rebecca Gelman, Hope S. Rugo, Lisa A. Carey, EP Winer, Erica L. Mayer, Kathy D. Miller, Harold J. Burstein, Jennifer A. Ligibel
Publikováno v:
Journal of Clinical Oncology. 28:TPS103-TPS103
TPS103 Background: Patients (pts) with residual breast cancer after neoadjuvant chemotherapy (C) are at increased risk of recurrence; no proven risk-reduction strategies exist, supporting exploration of novel therapies in the post-preoperative settin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d416925e4d97af935b2265a20e8b976b
https://doi.org/10.1200/jco.2010.28.15_suppl.tps103
https://doi.org/10.1200/jco.2010.28.15_suppl.tps103